Verve Therapeutics, VERV is showing recent insider trading activity. Public SEC records indicate that Krishna Yeshwant recently Bought $18,000,000 worth of shares on 1 week ago. With that said, our editors here at politicsandwallstreet.com, are adding VERV to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of VERV that Sold 288,674,341 worth of shares in the last 3 months, the Insider Confidence level of Verve Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at Verve Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for VERV:
In addition, TradingView issued a Buy rating for VERV over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook.
Cory Jubinville,
Here is a bit more on Verve Therapeutics, VERV but please do your own research.
VERV Summary: Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to VERV, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of VERV that Sold 288,674,341 worth of shares in the last 3 months, the Insider Confidence level of Verve Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at Verve Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for VERV:
- Krishna Yeshwant - officer: Chief Financial Officer, Bought $18,000,000 worth of shares on 5 days ago
- Allison Dorval - director, 10 percent owner:, Sold $6,343 worth of shares on 1 week ago
- Andrew Bellinger - officer: CSO & CMO, Sold $19,852 worth of shares on 1 year ago
- Allison Dorval - officer: Chief Financial Officer, Sold $12,243 worth of shares on 1 year ago
In addition, TradingView issued a Buy rating for VERV over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook.
Cory Jubinville,
Here is a bit more on Verve Therapeutics, VERV but please do your own research.
VERV Summary: Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.
- Recent Last Price: $12.49
- Price Change: $0.92, 7.95%
- Yearly Gain: -45.09%
- Market Cap: $943.37M
- P/E Ratio: -3.726
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to VERV, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
